PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/565, 47/36 — A1

(11) International Publication Number: WO 98/47517

(43) International Publication Date: 29 October 1998 (29.10.98)

(21) International Application Number: PCT/EP98/02361

(22) International Filing Date: 20 April 1998 (20.04.98)

(30) Priority Data:
97201180.3 22 April 1997 (22.04.97) EP
(34) Countries for which the regional or international application was filed: NL et al.

(71) Applicant *(for all designated States except US)*: AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL–6824 BM Arnhem (NL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HAAN DE, Pieter [NL/NL]; Drijvershof 18, NL–5343 XB Oss (NL). ROVERS, Adrianus, Cornelis, Petrus [NL/NL]; Azaleastraat 9, NL–5691 SK Son (NL). LAMBREGTS–DE HURK, Theodora, Antonia, Maria [NL/NL]; Gen. von Vlijmenstraat 5, NL–5463 CH Veghel (NL). ZWINKELS, Jocominus, Antonius, Maria [NL/NL]; Maxend 7, NL–5388 GH Nistelrode (NL). MORITA, Ryoichi [JP/JP]; 5–15, Higashinaka 2–chome, Yamatotakada–shi, Nara 635–0065 (JP).

(74) Agent: KRAAK, Hajo; P.O. Box 20, NL–5340 BH Oss (NL).

(81) Designated States: AM, AU, BB, BG, BR, CA, CN, CZ, EE GE, HU, ID, IS, KE, KG, KP, KR, KZ, LK, LR, LT, LV MD, MG, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: STABILIZED TIBOLONE COMPOSITIONS

(57) Abstract

The invention pertains to a pharmaceutical dosage unit, such as a tablet or a capsule, comprising an effective amount of tibolone (generally of from 0.1 to 10 % by weight) and a starch–containing pharmaceutically acceptable carrier (also denoted as basic granulate), wherein the carrier contains of from 10 to 100 % by weight of the starch. Thus a more stable tibolone formulation is obtained, allowing dry storage and lower doses of active ingredient.